Cardiol Therapeutics akcijos akcijų analizė | Akcijų kaina | Naujienos | CRDL.TO | CA14161Y2006 | A2PA9E

Data	Cardiol Therapeutics Akcijų kaina
2025-01-08	1,87 undefined
2025-01-07	1,97 undefined
2025-01-06	1,99 undefined
2025-01-03	2,08 undefined
2025-01-02	1,97 undefined
2024-12-31	1,85 undefined
2024-12-30	1,84 undefined
2024-12-27	1,89 undefined
2024-12-24	1,81 undefined
2024-12-23	1,80 undefined
2024-12-20	1,87 undefined
2024-12-19	1,89 undefined
2024-12-18	1,96 undefined
2024-12-17	1,95 undefined
2024-12-16	1,91 undefined
2024-12-13	1,89 undefined
2024-12-12	1,93 undefined
2024-12-11	2,03 undefined
2024-12-10	2,04 undefined

Data	Cardiol Therapeutics Pajamos	Cardiol Therapeutics EBIT	Cardiol Therapeutics Pelnas
2029e	195,46 mln. undefined	143,04 mln. undefined	128,48 mln. undefined
2028e	128,50 mln. undefined	79,99 mln. undefined	89,68 mln. undefined
2027e	45,34 mln. undefined	2,47 mln. undefined	18,59 mln. undefined
2026e	1,53 mln. undefined	−38,86 mln. undefined	−51,67 mln. undefined
2025e	0 undefined	−40,06 mln. undefined	−38,83 mln. undefined
2024e	0 undefined	−38,17 mln. undefined	−41,67 mln. undefined
2023	0 undefined	−29,79 mln. undefined	−28,13 mln. undefined
2022	0 undefined	−41,34 mln. undefined	−30,93 mln. undefined
2021	80 000,00 undefined	−38,66 mln. undefined	−31,64 mln. undefined
2020	0 undefined	−20,69 mln. undefined	−20,64 mln. undefined
2019	0 undefined	−14,13 mln. undefined	−13,68 mln. undefined
2018	0 undefined	−7,10 mln. undefined	−15,89 mln. undefined
2017	0 undefined	−1,60 mln. undefined	−1,66 mln. undefined

	Pajamos	EBIT	Pelnas
2017	0 CAD	−1,60 mln. CAD	−1,66 mln. CAD
2018	0 CAD	−7,10 mln. CAD	−15,89 mln. CAD
2019	0 CAD	−14,13 mln. CAD	−13,68 mln. CAD
2020	0 CAD	−20,69 mln. CAD	−20,64 mln. CAD
2021	80 000,00 CAD	−38,66 mln. CAD	−31,64 mln. CAD
2022	0 CAD	−41,34 mln. CAD	−30,93 mln. CAD
2023	0 CAD	−29,79 mln. CAD	−28,13 mln. CAD
2024e	0 CAD	−38,17 mln. CAD	−41,67 mln. CAD
2025e	0 CAD	−40,06 mln. CAD	−38,83 mln. CAD
2026e	1,53 mln. CAD	−38,86 mln. CAD	−51,67 mln. CAD
2027e	45,34 mln. CAD	2,47 mln. CAD	18,59 mln. CAD
2028e	128,50 mln. CAD	79,99 mln. CAD	89,68 mln. CAD
2029e	195,46 mln. CAD	143,04 mln. CAD	128,48 mln. CAD

2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e
0	0	0	0	0	0	0	0	0	1,00	45,00	128,00	195,00
-	-	-	-	-	-	-	-	-	-	4 400,00	184,44	52,34
-	-	-	-	-	-	-	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	0	0	0	0
−1,00	−15,00	−13,00	−20,00	−31,00	−30,00	−28,00	−41,00	−38,00	−51,00	18,00	89,00	128,00
-	1 400,00	−13,33	53,85	55,00	−3,23	−6,67	46,43	−7,32	34,21	−135,29	394,44	43,82
22,73	25,80	25,82	29,86	43,22	62,51	64,46	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-

2017	2018	2019	2020	2021	2022	2023

2,36	16,73	6,96	14,03	83,90	59,47	34,93
10,00	30,00	10,00	10,00	70,00	210,00	142,75
90,00	430,00	920,00	210,00	340,00	270,00	137,12
0	0	1,12	0,02	0	0	0
0,03	6,83	5,37	0,69	2,83	1,49	0,94
2,49	24,02	14,38	14,96	87,14	61,44	36,15
20,00	30,00	580,00	480,00	360,00	300,00	337,06
0	0	0	0	0	0	0
0	0	0	0	341,00	270,00	0
720,00	630,00	550,00	460,00	380,00	290,00	210,36
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0,74	0,66	1,13	0,94	1,08	0,86	0,55
3,23	24,68	15,51	15,90	88,22	62,30	36,70

4,26	36,72	39,41	51,92	142,92	147,55	148,52
0	1,25	4,77	8,77	12,66	15,59	18,79
−1,66	−15,96	−29,51	−47,42	−79,34	−110,93	−139,06
0,26	0,26	0	0	4,18	3,52	0
0	0	0	0	0	0	0
2,86	22,27	14,67	13,27	80,42	55,73	28,25
0,18	2,14	0,64	2,47	4,86	9,33	8,04
0	0	0	0	718,00	985,00	0
0	0	0	0	6,66	0,42	0,24
0	0	0	0	0	0	0
0	0	50,00	50,00	40,00	50,00	15,81
0,18	2,14	0,69	2,52	12,28	10,79	8,30
190,00	270,00	140,00	100,00	70,00	20,00	158,53
0	0	0	0	0	0	0
0	0	0	0	0	0	0
190,00	270,00	140,00	100,00	70,00	20,00	158,53
0,37	2,41	0,83	2,62	12,35	10,81	8,45
3,23	24,68	15,50	15,89	92,77	66,54	36,70

2017	2018	2019	2020	2021	2022
−1,00	−15,00	−13,00	−20,00	−31,00	−30,00
0	0	0	0	0	0
0	0	0	0	0	0
0	−5,00	−1,00	8,00	0	5,00
0	10,00	3,00	2,00	7,00	−2,00
0	0	0	0	0	0
0	0	0	0	0	0
−1,00	−10,00	−11,00	−9,00	−23,00	−27,00
0	0	0	0	0	0
0	0	0	0	0	0
0	0	0	0	0	0
0	0	0	0	0	0
0	12,00	0	0	0	0
3,00	14,00	2,00	17,00	98,00	0
3,00	25,00	2,00	16,00	93,00	0
-	−1,00	-	−1,00	−5,00	-
0	0	0	0	0	0
2,00	14,00	−9,00	7,00	69,00	−24,00
−1,32	−10,90	−11,80	−9,23	−23,56	−27,29
0	0	0	0	0	0

Cardiol Therapeutics Bruto marža	Cardiol Therapeutics Pelnas-martža	Cardiol Therapeutics EBIT marža	Cardiol Therapeutics Pelnas-martža
2029e	98,75 %	73,18 %	65,73 %
2028e	98,75 %	62,25 %	69,79 %
2027e	98,75 %	5,44 %	41,00 %
2026e	98,75 %	−2 535,12 %	−3 370,32 %
2025e	98,75 %	0 %	0 %
2024e	98,75 %	0 %	0 %
2023	98,75 %	0 %	0 %
2022	98,75 %	0 %	0 %
2021	98,75 %	−48 325,00 %	−39 550,00 %
2020	98,75 %	0 %	0 %
2019	98,75 %	0 %	0 %
2018	98,75 %	0 %	0 %
2017	98,75 %	0 %	0 %

	Bruto marža	EBIT marža	Pelnas-martža
2017	98,75 %	0 %	0 %
2018	98,75 %	0 %	0 %
2019	98,75 %	0 %	0 %
2020	98,75 %	0 %	0 %
2021	98,75 %	−48 325,00 %	−39 550,00 %
2022	98,75 %	0 %	0 %
2023	98,75 %	0 %	0 %
2024e	98,75 %	0 %	0 %
2025e	98,75 %	0 %	0 %
2026e	98,75 %	−2 535,12 %	−3 370,32 %
2027e	98,75 %	5,44 %	41,00 %
2028e	98,75 %	62,25 %	69,79 %
2029e	98,75 %	73,18 %	65,73 %

Data	Cardiol Therapeutics Pardavimai vienai akcijai	Cardiol Therapeutics EBIT vienai akcijai	Cardiol Therapeutics Pelnas vienai akcijai
2029e	2,39 undefined	0 undefined	1,57 undefined
2028e	1,57 undefined	0 undefined	1,10 undefined
2027e	0,55 undefined	0 undefined	0,23 undefined
2026e	0,02 undefined	0 undefined	−0,63 undefined
2025e	0 undefined	0 undefined	−0,48 undefined
2024e	0 undefined	0 undefined	−0,51 undefined
2023	0 undefined	−0,46 undefined	−0,44 undefined
2022	0 undefined	−0,66 undefined	−0,49 undefined
2021	0,00 undefined	−0,89 undefined	−0,73 undefined
2020	0 undefined	−0,69 undefined	−0,69 undefined
2019	0 undefined	−0,55 undefined	−0,53 undefined
2018	0 undefined	−0,28 undefined	−0,62 undefined
2017	0 undefined	−0,07 undefined	−0,07 undefined

	Pardavimai vienai akcijai	EBIT vienai akcijai	Pelnas vienai akcijai
2017	0 CAD	−0,07 CAD	−0,07 CAD
2018	0 CAD	−0,28 CAD	−0,62 CAD
2019	0 CAD	−0,55 CAD	−0,53 CAD
2020	0 CAD	−0,69 CAD	−0,69 CAD
2021	0,00 CAD	−0,89 CAD	−0,73 CAD
2022	0 CAD	−0,66 CAD	−0,49 CAD
2023	0 CAD	−0,46 CAD	−0,44 CAD
2024e	0 CAD	0 CAD	−0,51 CAD
2025e	0 CAD	0 CAD	−0,48 CAD
2026e	0,02 CAD	0 CAD	−0,63 CAD
2027e	0,55 CAD	0 CAD	0,23 CAD
2028e	1,57 CAD	0 CAD	1,10 CAD
2029e	2,39 CAD	0 CAD	1,57 CAD

	Akcijų skaičius
2017	22,73 mln. Aktien
2018	25,80 mln. Aktien
2019	25,82 mln. Aktien
2020	29,86 mln. Aktien
2021	43,22 mln. Aktien
2022	62,51 mln. Aktien
2023	64,46 mln. Aktien
2024e	64,46 mln. Aktien
2025e	64,46 mln. Aktien
2026e	64,46 mln. Aktien
2027e	64,46 mln. Aktien
2028e	64,46 mln. Aktien
2029e	64,46 mln. Aktien

Data	EPS-prognozė	EPS-Faktinis	Pranešimo ketvirtis
2024-09-30	−0,12	−0,18 (−47,06 %)	2024 Q3
2024-06-30	−0,13	−0,10 (24,59 %)	2024 Q2
2024-03-31	−0,13	−0,14 (−5,58 %)	2024 Q1
2023-12-31	−0,12	−0,12 (1,96 %)	2023 Q4
2023-09-30	−0,12	−0,09 (26,47 %)	2023 Q3
2023-06-30	−0,13	−0,12 (5,88 %)	2023 Q2
2023-03-31	−0,15	−0,11 (28,10 %)	2023 Q1
2022-12-31	−0,16	−0,12 (24,10 %)	2022 Q4
2022-09-30	−0,15	−0,13 (12,10 %)	2022 Q3
2022-06-30	−0,14	−0,10 (29,97 %)	2022 Q2
2022-03-31	−0,17	−0,14 (19,26 %)	2022 Q1
2021-12-31	−0,15	−0,11 (28,10 %)	2021 Q4
2021-06-30	−0,14	−0,16 (−12,04 %)	2021 Q2
2021-03-31	−0,14	−0,26 (−82,07 %)	2021 Q1
2020-12-31	−0,12	−0,15 (−22,55 %)	2020 Q4
2020-03-31	−0,16	−0,11 (32,60 %)	2020 Q1
2019-12-31	−0,13	−0,12 (9,50 %)	2019 Q4

%	Pavadinimas	Akcijos	Pokytis	Data
2,10801 %	Tejara Capital Ltd.	1 722 243	77 833	2024-06-30
1,96987 %	Merlin Asset Management	1 609 385	−118 442	2023-04-30
1,79556 %	AdvisorShares Investments, LLC	1 466 972	164 994	2024-06-30
1,47430 %	Elsley (David G)	1 204 500	50 000	2024-06-24
1,13112 %	MMCAP Asset Management	924 125	−1 642 000	2024-06-30
1,06069 %	Willner (Michael Jay)	866 585	80 244	2024-09-06
0,73439 %	Palos Management Inc.	600 000	0	2024-08-31
0,57196 %	Pekos (Peter)	467 290	0	2024-05-13
0,54800 %	Hamer (Andrew Warwick M.D.)	447 713	133 333	2024-10-25
0,36716 %	Global X Investments Canada Inc.	299 967	148 524	2024-09-30
0,33449 %	Lion Street Advisors, LLC	273 281	20 000	2024-09-30
0,23193 %	Penserra Capital Management LLC	189 490	−146 807	2023-03-31
0,19823 %	Foundations Investment Advisors, LLC	161 950	113 950	2024-09-30
0,18649 %	Torreamione (Guilermo)	152 364	63 200	2024-05-13
0,17442 %	Stott (Colin George)	142 500	0	2024-05-13
0,14688 %	Loxam (Teri)	120 000	60 000	2024-09-06
0,13464 %	Waddick (Christopher J)	110 000	0	2024-05-13
0,12240 %	MGO One Seven LLC	100 000	0	2024-09-30
0,12240 %	Laird Norton Wealth Management	100 000	0	2024-06-30
0,12240 %	Chao (Jennifer M)	100 000	100 000	2024-09-06
0,12240 %	Knoll Capital Management, LLC	100 000	100 000	2024-06-30
0,08100 %	Susquehanna International Group, LLP	66 180	20 511	2024-06-30
0,07466 %	Cambridge Investment Research Advisors, Inc.	61 001	−55 130	2024-09-30
0,06732 %	UBS Asset Management (UK) Ltd.	55 000	55 000	2024-06-30
0,06418 %	Geode Capital Management, L.L.C.	52 435	0	2024-06-30
0,06120 %	BMO Capital Markets (US)	50 000	0	2024-06-30
0,05213 %	BlackRock Institutional Trust Company, N.A.	42 590	42 590	2024-09-30
0,04517 %	Marble Harbor Investment Counsel, LLC	36 900	0	2024-06-30
0,03672 %	Lim (Bernard)	30 000	0	2024-02-29
0,03586 %	Arrowstreet Capital, Limited Partnership	29 294	29 294	2024-06-30
0,03463 %	Group One Trading, L.P.	28 292	24 625	2024-06-30
0,03205 %	Citadel Advisors LLC	26 187	−34 211	2024-06-30
0,03203 %	Envestnet Asset Management, Inc.	26 167	787	2024-06-30
0,03035 %	RBC Dominion Securities, Inc.	24 795	10 676	2024-06-30
0,02876 %	Goldman Sachs International	23 500	0	2024-06-30
0,02118 %	Morgan Stanley Canada Limited	17 300	17 300	2024-06-30
0,01958 %	First Capital Management Group GmbH	16 000	0	2024-08-31
0,01854 %	Wealthspire Advisors	15 151	0	2024-06-30
0,01677 %	Wealth Enhancement Advisory Services, LLC	13 700	13 700	2024-09-30
0,01530 %	Faircourt Asset Management Inc.	12 500	0	2024-08-31
0,01367 %	Adhesion Wealth Advisor Solutions	11 165	11 165	2024-06-30
0,01360 %	Verition Fund Management LLC	11 109	11 109	2024-06-30
0,01224 %	Morgan Stanley & Co. LLC	10 000	10 000	2024-06-30
0,00979 %	CIBC Private Wealth Management	8 000	8 000	2024-06-30
0,00845 %	TD Waterhouse Canada, Inc.	6 900	0	2024-03-31
0,00612 %	Piscataqua Savings Bank	5 000	0	2024-09-30
0,00612 %	Valley National Advisers Inc.	5 000	0	2024-09-30
0,00490 %	HFM Wealth Management	4 000	0	2024-09-30
0,00490 %	BofA Global Research (US)	4 000	0	2024-06-30
0,00367 %	Wells Fargo Advisors	3 000	0	2024-06-30
0,00306 %	UBS Financial Services, Inc.	2 500	−281	2024-06-30
0,00245 %	National Bank of Canada	2 000	−120	2024-06-30
0,00245 %	RBC Private Counsel (USA) Inc.	2 000	0	2024-06-30
0,00147 %	Osaic Holdings, Inc.	1 200	−24 400	2024-06-30
0,00122 %	South State Bank	1 000	0	2024-06-30
0,00122 %	Rise Advisors, LLC	1 000	0	2024-09-30
0,00107 %	Benjamin Edwards, Inc	875	0	2024-06-30
0,00098 %	TD Securities, Inc.	803	700	2024-06-30
0,00049 %	Central Trust & Investment Company	400	400	2024-09-30
0,00038 %	RBC Capital Markets Wealth Management	310	0	2024-06-30
0,00014 %	BMO Nesbitt Burns Inc.	112	112	2024-06-30
0,00006 %	Stone House Investment Management, LLC	50	50	2024-06-30
0 %	Townsquare Capital, LLC	0	−12 661	2024-06-30
0 %	Simplex Trading, LLC	0	−1 054	2023-12-31
0 %	Vident Investment Advisory, LLC	0	−146 807	2023-03-31
0 %	HRT Financial LP	0	−12 345	2023-12-31
0 %	Tradewinds Capital Management, LLC	0	−500	2023-03-31
0 %	Advisory Services Network, LLC	0	−3 458	2024-03-31
0 %	NewSquare Capital LLC	0	−700	2023-09-30
0 %	Mirae Asset Global Investments (USA) LLC	0	−1 094 040	2023-03-31
0 %	Baader Bank AG	0	−29 028	2024-09-30
0 %	Jane Street Capital, L.L.C.	0	−20 875	2023-06-30
0 %	Tower Research Capital LLC	0	−22 456	2023-03-31
0 %	IQ EQ Fund Management (Ireland) Limited	0	−11 137	2023-03-31
0 %	Two Sigma Investments, LP	0	−31 181	2024-06-30
0 %	Desjardins Securities Inc.	0	−1 800	2024-03-31
0 %	Ostrum Asset Management	0	−25 000	2023-09-30
0 %	Renaissance Technologies LLC	0	−10 100	2023-06-30
0 %	UBS Fund Management (Switzerland) AG	0	−80 000	2024-06-30
0 %	Raymond James & Associates, Inc.	0	−11 154	2024-06-30
0 %	PNC Investments LLC	0	−100	2023-06-30
0 %	Goldman Sachs & Company, Inc.	0	−24 600	2023-06-30
0 %	Dimensional Fund Advisors, L.P.	0	−11 500	2024-02-29
0 %	Oliver LaGore VanValin Investment Group, Inc	0	−500	2023-09-30
0 %	City State Bank	0	−825	2024-06-30
0 %	AXS Investments LLC	0	−697 651	2024-03-31
0 %	MONECO Advisors, LLC	0	−14 000	2023-12-31
0 %	Robertson Stephens Wealth Management, LLC	0	−27 855	2023-06-30
0 %	FNY Investment Advisers LLC	0	−33 305	2023-12-31

Pavadinimas	Santykis	Dviejų savaičių koreliacija	Vieno mėnesio koreliacija	Trymėnesio koreliacija	Šešių mėnesių koreliacija	Vienmečio koreliacija	Dviejų metų koreliacija
Loblaw Compan	TiekėjasKlientas	0,07	0,51	0,11	-0,62	-0,58	-0,37
Seikagaku	TiekėjasKlientas	-0,17	0,59	0,45	0,77	0,74	0,52

What values and corporate philosophy does Cardiol Therapeutics represent?

Cardiol Therapeutics Inc represents a strong commitment to improving cardiovascular health through innovative therapies. With a core philosophy centered around scientific excellence and patient-centric approach, Cardiol aims to develop safe and effective cannabidiol-based pharmaceuticals. The company focuses on rigorous research and development, clinical trials, and strategic partnerships to deliver breakthrough treatments for heart diseases. By prioritizing the well-being of patients, Cardiol Therapeutics Inc strives to redefine cardiovascular care and contribute to healthier lives.

In which countries and regions is Cardiol Therapeutics primarily present?

Cardiol Therapeutics Inc is primarily present in various countries and regions around the world. The company has a global reach and engages in its operations in multiple places. With its headquarters in Canada, Cardiol Therapeutics Inc has a strong presence in North America, particularly in the United States. Additionally, the company has established partnerships and collaborations globally, allowing it to extend its reach to other regions and countries. Cardiol Therapeutics Inc's commitment to expanding its market presence ensures its innovative healthcare solutions reach patients and healthcare professionals worldwide.

What significant milestones has the company Cardiol Therapeutics achieved?

Cardiol Therapeutics Inc has achieved several significant milestones. The company successfully completed its Phase 2 clinical trial evaluating CardiolRx™ for the treatment of acute myocarditis, a severe inflammatory condition of the heart. Additionally, Cardiol Therapeutics Inc received a patent grant from the United States Patent and Trademark Office for its unique methods in treating various forms of heart failure using cannabinoids. The company also obtained a license agreement with Dalton Pharma Services, a leading contract development and manufacturing organization, to support the production of pharmaceutical-grade cannabidiol. These milestones demonstrate Cardiol Therapeutics Inc's dedication to advancing innovative therapies and solidify its position in the pharmaceutical industry.

What is the history and background of the company Cardiol Therapeutics?

Cardiol Therapeutics Inc. is a pharmaceutical company specializing in the development and commercialization of cutting-edge therapies for cardiovascular diseases. Founded in 2013, Cardiol Therapeutics has quickly emerged as a leader in the field, with a strong focus on cannabinoid-based treatments. The company's innovative research and development efforts have resulted in the development of CardiolRx™, a proprietary pharmaceutical cannabidiol formulation that targets heart diseases. With a relentless dedication to improving patient outcomes, Cardiol Therapeutics is committed to bringing forth effective and safe medicinal solutions for various cardiovascular conditions. They continuously collaborate with leading researchers and medical professionals to advance their mission of revolutionizing cardiovascular care.

Who are the main competitors of Cardiol Therapeutics in the market?

The main competitors of Cardiol Therapeutics Inc in the market include companies like GW Pharmaceuticals, Amarin Corporation, Novartis Pharmaceuticals, and Pfizer Inc.

In which industries is Cardiol Therapeutics primarily active?

Cardiol Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Cardiol Therapeutics?

The business model of Cardiol Therapeutics Inc revolves around the development and commercialization of pharmaceutical products. The company focuses on producing innovative therapies for various medical conditions, particularly those related to heart diseases. Cardiol Therapeutics Inc aims to leverage advanced scientific research and technologies to create effective treatments for cardiovascular disorders. With a strong commitment to improving patients' lives, the company actively engages in clinical trials and collaborations with experts in the field. Cardiol Therapeutics Inc strives to provide solutions that address significant unmet medical needs, positioning itself as a leader in the cardiovascular health industry.

Koks yra Cardiol Therapeutics 2025 KGV?

Cardiol Therapeutics KGV yra −3,10.

Koks Cardiol Therapeutics 2025 KUV?

Cardiol Therapeutics KUV yra 0.

Koks yra Cardiol Therapeutics AlleAktien kokybės įvertinimas?

AlleAktien kokybės įvertis Cardiol Therapeutics yra 2/10.

Koks yra Cardiol Therapeutics 2025 pajamų dydis?

Pajamos šiuo metu negali būti apskaičiuotos Cardiol Therapeutics.

Kokia yra Cardiol Therapeutics 2025 pelnas?

tikėtina Cardiol Therapeutics pelnas yra −38,83 mln. CAD.

Ką daro Cardiol Therapeutics?

Cardiol Therapeutics Inc is a Canadian biopharmaceutical company specializing in the development of innovative therapies for the treatment of cardiovascular diseases. The company is headquartered in Oakville, Ontario and is listed on the Toronto Stock Exchange and the NASDAQ. Cardiol Therapeutics' business model is based on the research, development, and commercialization of novel treatments for cardiovascular system diseases, including chronic heart failure, coronary artery disease, and heart attack. The company focuses on the application of cannabinoids as the basis for its therapeutics. Cardiol Therapeutics' flagship product is the drug candidate CardiolRx, a synthetic cannabidiol (CBD) derivative. It is intended to improve endogenous repair mechanisms after a heart attack. The company has successfully completed the clinical development of CardiolRx; the Phase 3 study (TIMI 3 study) has demonstrated the effectiveness and safety of the drug candidate in patients with heart attack. The approval of CardiolRx is currently being sought from regulatory authorities in the United States and Europe. CardiolRx is being conducted by Cardiol Therapeutics itself. However, CardiolRx is not the only product that Cardiol Therapeutics has in its pipeline. The company has a portfolio of drug candidates that include both synthetic cannabinoids and natural products. Currently, the company is developing another cannabinoid-based medication, CardiolRx + CBD. This product is a combination of the already approved CardiolRx and natural CBD. CardiolRx + CBD is currently undergoing clinical trials. In addition to its pharmaceutical products, Cardiol Therapeutics also operates a research program focused on studying the therapeutic effects of cannabinoids on the cardiovascular system. The company aims to understand the mechanisms of action of cannabinoids on the heart and develop further medical applications. In addition to its research and development work, Cardiol Therapeutics has also entered into partnerships with other companies. In 2019, the company signed an agreement with Apic Bio to jointly develop gene therapy for the treatment of heart failure. Under this agreement, Apic Bio will assist in preparing an Investigational New Drug (IND) submission to the FDA. Cardiol Therapeutics' business model is based on an innovative research platform and a broad pipeline of drug candidates that utilize the therapeutic effects of cannabinoids on the cardiovascular system. The company aims to solidify its leading position in this field and market its products globally. With its experienced management team and strong research results, Cardiol Therapeutics is expected to continue to be successful and have the potential to save lives and improve the health of millions of people worldwide. The main focus of Cardiol Therapeutics is the development of innovative therapies for cardiovascular diseases using cannabinoids. They have successfully completed the clinical development of CardiolRx and are seeking approval for its use in treating heart attack patients. They are also developing other cannabinoid-based medications, such as CardiolRx + CBD. The company also conducts research on the therapeutic effects of cannabinoids on the cardiovascular system. They have partnerships with other companies, such as Apic Bio, to develop gene therapy for heart failure. The company aims to solidify its position in the market and globally market its products.

Kokia yra Cardiol Therapeutics dividendė?

Cardiol Therapeutics moka dividendą 0 CAD, kuris yra paskirstytas per išmokas per metus.

Kiek kartų Cardiol Therapeutics moka dividendą?

Dividenda šiuo metu negali būti apskaičiuota Cardiol Therapeutics arba įmonė dividendų nemoka.

Kas yra Cardiol Therapeutics ISIN?

Cardiol Therapeutics ISIN yra CA14161Y2006.

Kas yra Cardiol Therapeutics WKN?

Cardiol Therapeutics WKN yra A2PA9E.

Kas yra Cardiol Therapeutics Tickeris?

Cardiol Therapeutics akcijų simbolis yra CRDL.TO.

Kiek dividendų moka Cardiol Therapeutics?

Per paskutinius 12 mėnesių Cardiol Therapeutics išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams Cardiol Therapeutics tikėtina išmokės dividendus, kurie sudarys 0 CAD.

Kokia yra Cardiol Therapeutics dividendų grąža?

Cardiol Therapeutics šiuo metu yra dydžio dividendų grąža.

Kada Cardiol Therapeutics moka dividendus?

Cardiol Therapeutics moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Kokia saugi yra Cardiol Therapeutics dividendų išmokėjimas?

Cardiol Therapeutics per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Kokia yra Cardiol Therapeutics dividendų suma?

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 CAD. Tai atitinka 0 % dividendų grąžos procentą.

Kokiame sektoriuje yra Cardiol Therapeutics?

Cardiol Therapeutics priskiriamas sektoriui "Sveikata".

Wann musste ich die Aktien von Cardiol Therapeutics kaufen, um die vorherige Dividende zu erhalten?

Norėdamas gauti paskutinį Cardiol Therapeutics dividendą nuo 2025-01-08, kurio dydis yra 0 CAD, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2025-01-08.

Kada Cardiol Therapeutics paskutinį kartą mokėjo dividendą?

Paskutinės dividendų išmokėjimas įvyko 2025-01-08.

Kokia buvo Cardiol Therapeutics dividendų suma 2024 metais?

2024 metais Cardiol Therapeutics išmokėjo 0 CAD dividendų.

Kokia valiuta Cardiol Therapeutics moka dividendus?

Cardiol Therapeutics dividendai yra mokami CAD.

Tiesioginiai išleidimai
Netiesioginės emisijos iš įsigytos energijos
Tiesioginiai išmetimai iš vertybių grandinės
CO₂ emisijos
CO₂ mažinimo strategija
Anglies energija
Atomkraft
Bandymai su gyvūnais
Pelz & Leder
Pesticidai
Palmių aliejus
Tabakas
Genetinė inžinerija
Klimato koncepcija
Tvarioji miškininkystė
Perdirbimo nuostatai
Aplinkai draugiška pakuotė
Pavojingosios medžiagos
Degalų sąnaudos ir efektyvumas
Vandens suvartojimas ir efektyvumas

Moterų dalis tarp darbuotojų
Moterų dalis valdyme
Azijietiškų darbuotojų dalis
Akcijų dalis Azijos valdyme
Hispanų/lotynų kilmės darbuotojų dalis
Hispanų/latino kilmės vadybos dalis
Akcijų turimų tamsios odos darbuotojų procentas
Juodaodžių valdymo dalis
Baltųjų darbuotojų dalis
Baltųjų valdymo dalis
Suaugusiųjų turinys
Alkoholis
Ginkluotė
Šaunamieji ginklai
Azartiniai lošimai
Karinių sutarčių
Žmogaus teisių koncepcija
Privatumo politika
Darbo ir sveikatos apsauga
Katalikiškas

Tvarumo ataskaita
Akcijų turėtojų įtraukimas
Atsiliepimo taisyklės
Kartelio teisė

Birža	Cardiol Therapeutics Akcijų kodas
DIUSELDORFAS	CT9.DU
FRANKFURTAS	CT9.F
MIUNCHENAS	CT9.MU
NASDAQ	CRDL
TSX	CRDL.TO

Cardiol Therapeutics Akcijų kodas	Cardiol Therapeutics FIGI
CRDL:CN	BBG00M0GNP68
CRDL:CT	BBG00M0GNP86
CRDL:CJ	BBG00M0GNPF8
CRDL:TR	BBG00M0GNPH6
CRDL:TX	BBG00M0GNPK2
CRDL:TA	BBG00M0GNPL1
CRDL:TG	BBG00M0GNPN9
CRDL:TK	BBG00M0GNPP7
CRDL:TW	BBG00M0GNPQ6
CRDL:DT	BBG00M0GNPW9
CRDL:DG	BBG00M0GNPX8
CRDL:QF	BBG00M0GNPY7
CRDL:QH	BBG00M0GNPZ6
CRDL:DJ	BBG00M0GNQ02
CRDL:QG	BBG00M0GNQ66
CRDL:US	BBG00N2N8310
CRDL:UA	BBG00N2N8329
CRDL:UC	BBG00N2N8338
CRDL:UN	BBG00N2N8365
CRDL:UP	BBG00N2N8374
CRDL:UB	BBG00N2N8392
CRDL:UM	BBG00N2N83C8
CRDL:UX	BBG00N2N83D7
CRDL:UR	BBG00N2N83F5
CRDL:PQ	BBG00N2N83H3
CRDL:UD	BBG00N2N83K9
CRDL:UF	BBG00N2N83N6
CRDL:VY	BBG00N2N83P4
CRDL:VJ	BBG00N2N83Q3
CRDL:VK	BBG00N2N83R2
CRDL:VF	BBG00N2N83S1
CT9:GR	BBG00Z0Y6J09
CT9:GF	BBG00Z0Y6J18
CT9:GD	BBG00Z0Y6J27
CT9:GS	BBG00Z0Y6J45
CT9:GM	BBG00Z0Y6J54
CT9:GB	BBG00Z0Y6J63
CRDLEUR:XS	BBG00Z19NPL7
CRDLEUR:X2	BBG00Z19NPM6
CRDLEUR:XH	BBG00Z19NPP3
CRDLEUR:XF	BBG00Z19NPR1
CRDLEUR:XE	BBG00Z19NPT9
CRDLEUR:XJ	BBG00Z19NPV6
CRDLEUR:XL	BBG00Z19NPW5
CRDLEUR:XG	BBG00Z19NPX4
CRDLEUR:XO	BBG00Z19NPY3
CRDLEUR:XA	BBG00Z19NQ26
CRDLEUR:E1	BBG00Z19NQ35
CRDLEUR:XT	BBG00Z19NQ44
CRDLEUR:XW	BBG00Z19NQ53
CRDLEUR:XU	BBG00Z19NQ62
CRDLEUR:XV	BBG00Z19NQ80
CRDLEUR:XM	BBG00Z19NQ99
CRDLEUR:XQ	BBG00Z19NQB6
CRDLEUR:XX	BBG00Z19NQC5
CRDLEUR:XZ	BBG00Z19NQD4
CRDLEUR:X1	BBG00Z19NQG1
CRDLEUR:EU	BBG00Z19NQJ8
CRDLGBP:XS	BBG00Z1YTBX4
CRDLGBP:X2	BBG00Z1YTBY3
CRDLGBP:XH	BBG00Z1YTC08
CRDLGBP:XF	BBG00Z1YTC26
CRDLGBP:XE	BBG00Z1YTC44
CRDLGBP:XJ	BBG00Z1YTC53
CRDLGBP:XL	BBG00Z1YTC62
CRDLGBP:XG	BBG00Z1YTC71
CRDLGBP:XO	BBG00Z1YTC80
CRDLGBP:XA	BBG00Z1YTCD4
CRDLGBP:E1	BBG00Z1YTCF2
CRDLGBP:XT	BBG00Z1YTCG1
CRDLGBP:XW	BBG00Z1YTCH0
CRDLGBP:XU	BBG00Z1YTCJ8
CRDLGBP:XV	BBG00Z1YTCL5
CRDLGBP:XM	BBG00Z1YTCM4
CRDLGBP:XQ	BBG00Z1YTCN3
CRDLGBP:XX	BBG00Z1YTCP1
CRDLGBP:XZ	BBG00Z1YTCQ0
CRDLGBP:X1	BBG00Z1YTCS8
CRDLGBP:EU	BBG00Z1YTCW3
CRDLCAD:XS	BBG00Z1YTD79
CRDLCAD:X2	BBG00Z1YTD88
CRDLCAD:XH	BBG00Z1YTDB4
CRDLCAD:XF	BBG00Z1YTDD2
CRDLCAD:XE	BBG00Z1YTDG9
CRDLCAD:XJ	BBG00Z1YTDH8
CRDLCAD:XL	BBG00Z1YTDJ6
CRDLCAD:XG	BBG00Z1YTDK4
CRDLCAD:XO	BBG00Z1YTDL3
CRDLCAD:XA	BBG00Z1YTDQ8
CRDLCAD:E1	BBG00Z1YTDR7
CRDLCAD:XT	BBG00Z1YTDS6
CRDLCAD:XW	BBG00Z1YTDT5
CRDLCAD:XU	BBG00Z1YTDV2
CRDLCAD:XV	BBG00Z1YTDX0
CRDLCAD:XM	BBG00Z1YTDY9
CRDLCAD:XQ	BBG00Z1YTDZ8
CRDLCAD:XX	BBG00Z1YTF01
CRDLCAD:XZ	BBG00Z1YTF10
CRDLCAD:X1	BBG00Z1YTF38
CRDLCAD:EU	BBG00Z1YTF56
CRDLUSD:XS	BBG00Z4JG5C4
CRDLUSD:XH	BBG00Z4JG5G0
CRDLUSD:XF	BBG00Z4JG5J7
CRDLUSD:XE	BBG00Z4JG5L4
CRDLUSD:XJ	BBG00Z4JG5M3
CRDLUSD:XL	BBG00Z4JG5N2
CRDLUSD:XG	BBG00Z4JG5P0
CRDLUSD:XO	BBG00Z4JG5Q9
CRDLUSD:XA	BBG00Z4JG5W2
CRDLUSD:XT	BBG00Z4JG5Y0
CRDLUSD:XW	BBG00Z4JG5Z9
CRDLUSD:XU	BBG00Z4JG605
CRDLUSD:XV	BBG00Z4JG632
CRDLUSD:XM	BBG00Z4JG641
CRDLUSD:EU	BBG00Z4JG6F9
CT9:TH	BBG00Z71V2N8
CT9:GZ	BBG00Z8KDRV1
CT9:QT	BBG011KCHNM4
CT9:LA	BBG018HBBCR0
CT9:LU	BBG018J3ZX76
CRDL:BF	BBG019LPMKF5
CRDL:HD	BBG01J14TKH3
CRDL:HX	BBG01J15JVD1

Padaryk geriausias savo gyvenimo investicijas

Kursas

Akcijos kaina

Akcijų kodasCRDL.TO

ISINCA14161Y2006

VVPA2PA9E

Cardiol Therapeutics akcijų kaina

Kursas

Apžvalga

Intraday funkcija

Bendroji grąža ir santykinė kainų pokyčiai

Interpretacija ir investavimas

Cardiol Therapeutics Akcijų istorija

Cardiol Therapeutics akcijų apyvarta, EBIT, pelnas CA14161Y2006 · A2PA9E

Pajamos, pelnas & EBIT

Supratimas apie pajamas, EBIT ir pelną

Metinė analizė ir palyginimai

Išnaudoti lūkesčius investuojant

Investicijų įžvalgos

Cardiol Therapeutics Pajamų, pelno ir EBIT istorija.

Cardiol Therapeutics Akcijų rodikliai

GuV

Pajamos ir augimas

Bruto marža

EBIT ir EBIT marža

Pajamos ir jų augimas

Leidžiamų akcijų skaičius

Metinių duomenų palyginimo interpretacija

Lūkesčiai ir prognozės

Balansas

Balanso supratimas

Turtas

Įsipareigojimai

Nuosavas kapitalas

Metų po metų analizė

Duomenų interpretacija

Cardiol Therapeutics Akcijos Maržos CA14161Y2006 · A2PA9E

Margen

Supratimas apie bruto maržą

EBIT maržos analizė

Pardavimų maržos įžvalgos

Lūkesčių interpretavimas

Lyginamoji analizė

Cardiol Therapeutics Maržų istorija

Cardiol Therapeutics akcijos apyvarta, EBIT, pelnas vienai akcijai CA14161Y2006 · A2PA9E

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Cardiol Therapeutics Pardavimų, pelno ir EBIT istorija vienai akcijai

Cardiol Therapeutics akcija ir akcijų analizė

Padaryk geriausias savo gyvenimo investicijas

Cardiol Therapeutics vertinimas pagal Fair Value

Fair Value

Supratimas apie Fair Value

Pajamų pagrindu skaičiuojamas Fair Value

Apyvartos pagrindu skaičiuojamas Fair Value

Dividendų pagrindu skaičiuojamas Fair Value

Lūkesčiai ir prognozės

Palyginamoji analizė

Cardiol Therapeutics įvertinimas pagal istorinį P/E, EBIT ir P/S

Padaryk geriausias savo gyvenimo investicijas

Cardiol Therapeutics akcijų skaičius CA14161Y2006 · A2PA9E

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Padaryk geriausias savo gyvenimo investicijas

Cardiol Therapeutics Pelno prognozės

Cardiol Therapeutics Pelnų staigmenos

Eulerpool ESG reitingas Cardiol Therapeutics akcijai

Eulerpool World ESG Rating (EESG©)

33/ 100

🌱 Environment

👫 Social

🏛️ Governance

Aplinka (Environment)

Socialinis (Social)

Akcijų kodas
CRDL.TO

ISIN
CA14161Y2006

VVP
A2PA9E